The NCPE recommends that osimertinib (Tagrisso®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The NCPE recommends that obinutuzumab (Gazyvaro®) in combination with chemotherapy followed by obinutuzumab maintenance therapy for this indication should not be considered for reimbursement, unless cost-effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The NCPE recommends that eliglustat (Cerdelga ®) should not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria as specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The NCPE recommends that blinatumomab not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013

The NCPE does not recommend reimbursement of Teduglutide (Revestive®) for the treatment of patients aged 1 year and above with short bowel syndrome.

The NCPE are delighted to facilitate  the delivery of the HTA module of the IPPOSI Pilot Patient Education Programme, commencing this Monday 22nd January. This module will provide students with a detailed knowledge of the principals of HTA, and has been adapted by the NCPE to provide particular insight into the practice of HTA in […]

The NCPE does not recommend the reimbursement of Nusinersen (Sprinraza®) for the treatment of 5q spinal muscular atrophy (SMA) at the submitted price.

The NCPE does not recommend reimbursement of Ixazombi (Ninlaro) in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

The NCPE do not recommend reimbursement of PROCYSBI for the treatment of nephropathic cystinosis patients.

The NCPE do not recommend reimbursement of Obeticholic acid (Ocaliva®) at the submitted price.